As a patient with rheumatoid arthritis and several other chronic conditions, I get excited to hear about promising new research, medical advances, and treatment options.
One of these new medications that I’ve been hearing about is by Russian pharma company R-Pharm. It’s an IL-6 inhibitor called olokizumab, and it just entered phase III clinical trials.
I was lucky enough to get to write about it for Healthline.
We may have to wait a while to see olokizumab on the market, but you can keep up with R-Pharm on Twitter, and view the press release and media info here, to stay on top of the progress as it enters Phase-3 trials.
The previous post contains sponsored content. Views are that of the author. The medical information on this post is provided as an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. This information should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider for medical questions or concerns.